You have 9 free searches left this month | for more free features.

Condition

Neovascular Age-related Macular Degeneration (2)

Diabetic Macular Edema (1)

Diabetic Macular Edema (DME) (1)

Overall Status

Active, not recruiting (1)

Completed (1)

Recruiting (1)

Sign in for free

Phase

phase 2 (2)

phase 1 (1)

Sponsor

Unity Biotechnology, Inc. (3)

Collaborator

Intervention

ubx1325 (3)

eylea® (aflibercept) injection 2 mg (0.05ml) (1)

sham (1)

Study Documents

Intervention Type

drug (3)

other (1)

Funder Type

Industry (3)

Study Type

Interventional (3)

ubx1325

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Diabetic Macular Edema, Neovascular Age-related Macular Degeneration Trial in United States (UBX1325)

Completed

Diabetic Macular Edema
Neovascular Age-related Macular Degeneration

UBX1325

Beverly Hills, California
+7 more

Mar 8, 2022

Diabetic Macular Edema (DME) Trial in Canada, United States (UBX1325, Sham)

Active, not recruiting

Diabetic Macular Edema (DME)

UBX1325
Sham

Phoenix, Arizona
+22 more

Apr 21, 2022

Neovascular Age-related Macular Degeneration Trial in United States (UBX1325, EYLEA® (aflibercept) Injection 2 mg (0.05mL))

Recruiting

Neovascular Age-related Macular Degeneration

UBX1325
EYLEA® (aflibercept) Injection 2 mg (0.05mL)

Beverly Hills, California
+24 more

May 19, 2022